|
1
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hurwits H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Iwasaki J and Nihira S: Anti-angiogenic
therapy against gastrointestinal tract cancers. Jpn J Clin Oncol.
16:1–9. 2009.
|
|
4
|
Yamaguchi K, Boku N, Kato K, Komatsu Y,
Muro K and Hamamoto Y: Preliminary efficacy, safety and operability
of bevacizumab plus capecitabine plus oxaliplatin (XELOX) as
first-line therapy in Japanese patients with initially unresectable
metastatic colorectal cancer. Ann Oncol. 19:viii1302008.
|
|
5
|
Karapetis CS, Khambata FS, Jonker DJ, et
al: K-ras mutations and benefit from cetuximab in advanced
colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Willett CG, Boucher Y, Duda DG, et al:
Surrogate markers for antiangiogenic therapy and dose-limiting
toxicities for bevacizumab with radiation and chemotherapy:
continued experience of a Phase I trial and rectal cancer patients.
J Clin Oncol. 22:8136–8139. 2005. View Article : Google Scholar
|
|
7
|
Galizia G, Lieto E, Ferraraccio F, et al:
Determination of molecular marker expression can predict clinical
outcome in colon carcinoma. Clin Cancer Res. 10:3490–3499. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takahashi Y, Kitadai Y, Bucana CD, Cleary
KR and Ellis LM: Expression of vascular endothelial growth factor
and its receptor, KDR, correlates with vascularity metastasis and
proliferation of human colon cancer. Cancer Res. 55:3964–3968.
1995.PubMed/NCBI
|
|
9
|
Werther K, Christensen IJ and Nielsen HJ:
Prognostic impact of matched preoperative plasma and serum VEGF in
patients with primary colorectal carcinoma. Br J Cancer.
86:417–423. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Broll R, Erdmann H, Duchrow M, et al:
Vascular endothelial growth factor (VEGF) – a valuable serum tumor
marker in patients with colorectal cancer? Eur J Surg Oncol.
27:37–42. 2001.
|
|
11
|
Willett CG, Boucher Y, Duda DG, et al:
Efficacy, safety and biomarkers of neoadjuvant bevacizumab,
radiation therapy and fluorouracil in rectal cancer: a
multidisciplinary phase II study. J Clin Oncol. 18:3020–3026. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Denduluri N, Yang SX, Berman AW, Nguyen D,
Liewehr DJ, Steinberg SM and Swalin SM: Circulating biomarkers of
bevacizumab activity in patients. Cancer Biol Ther. 7:15–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferrara N and Alitalo K: Clinical
application of angiogenic growth factors and their inhibitors. Nat
Med. 5:1359–1364. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shibuya M: Structure and function of
VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct
Func. 26:25–35. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kendall RL and Thomas KA: Inhibition of
vascular endothelial cell growth factor activity by an endogenously
encoded soluble receptor. Proc Natl Acad Sci USA. 90:10705–10709.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kendall RL, Wang G and Thomas KA:
Identification of a natural soluble form of the vascular
endothelial growth factor receptor, FLT-1, and its
heterodimerization with KDR. Biochem Biophys Res Commun.
226:324–328. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harris AL, Reusch P, Barlenon B, Hang C,
Dobbs N and Marme D: Soluble Tie2 and Flt1 extracellular domains in
serum of patients with renal cancer and response to antiangiogenic
therapy. Clin cancer Res. 7:1992–1997. 2001.PubMed/NCBI
|
|
18
|
Toi M, Bando H, Ogawa T, Muta M, Horing C
and Weich HA: Significance of vascular endothelial growth factor
(VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J
Cancer. 98:14–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tas F, Duranyildiz D, Oguz H, Camlica H,
Yasasever V and Topuz E: Circulating serum levels of angiogenic
factors and vascular endothelial growth factor receptors 1 and 2 in
melanoma patients. Melanoma Res. 16:405–411. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamaguchi T, Nando H, Mori T, et al:
Overexpression of soluble vascular endothelial growth factor
receptor 1 in colorectal cancer: association with progression and
prognosis. Cancer Sci. 98:405–410. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu Q, Dey AL, Yang Y, et al: Soluble
vascular endothelial growth factor receptor 1, and not receptor 2,
is an independent prognostic factor in acute myeloid leukemia and
myeloidysplastic syndromes. Cancer. 100:1884–1891. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hormbrey E, Gillespie P, Turner K, Han C,
Roberts A, McGrouther D and Harris AL: A critical review of
vascular endothelial growth factor (VEGF) analysis in peripheral
blood: is the current literature meaningful? Clin Exp Metastasis.
19:651–663. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Otrock ZK, Makarem JA and Shamseddine AI:
Vascular endothelial growth factor family of ligands and receptors:
review. Blood Cells Mol Dis. 38:258–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Poon RT, Fan ST and Wong J: Clinical
implication of circulating angiogenic factors in cancer patients. J
Clin Oncol. 19:1207–1225. 2001.PubMed/NCBI
|
|
25
|
Burstein A, Chen Y-H and Parker LM: VEGF
as a marker for outcome among advanced breast cancer patients
receiving anti-VEGF therapy with bevacizumab and vinorelbine
chemotherapy. Clin Cancer Res. 14:7871–7877. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Holden SN, Ryan E, Kearns A, Holmgren E
and Hurwitz H: Benefit from bevacizumab (BV) is independent of
pretreatment plasma vascular endothelial growth factor-A (pl-VEGF)
in patients (pts) with metastatic colorectal cancer (mCRC). J Clin
Oncol. 123:35552005.
|
|
27
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signaling – in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006.
|
|
28
|
Herold MC, Steiner HH, Andl T, et al:
Expression and functional significance of vascular endothelial
growth factor receptors in human tumor cells. Lab Invest.
79:1573–1582. 1999.PubMed/NCBI
|
|
29
|
Masood R, Cai J, Zheng T, Smith DL, Hinton
DR and Gill PS: Vascular endothelial growth factor (VEGF) is an
autocrine growth factor for VEGF receptor-positive human tumors.
Blood. 98:1904–1913. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Holash J, Davis S, Papadopoulos N, et al:
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl
Acad Sci USA. 99:11393–11398. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wierzbowska A, Robak T, Wizesien-Kus A,
Krawczynska A, Maranda EL and Urbanska-Rys H: Circulating VEGF and
its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute
leukemia. Eur Cytokine Netw. 14:149–153. 2003.PubMed/NCBI
|
|
33
|
AI-Moundhri M, Shukaili A, AI-Nabhani M,
AI-Bahrani B, Burney IA, Rozovo A and Ganguly SS: Measurement of
circulating levels of VEGF-A, -C and -D and their receptors,
VEGFR-1 and -2 in gastric adenocarcinoma. World Gastroenterol.
14:3879–3883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ustuner Z, Saip P, Yasasever V, et al:
Prognostic and predictive value of vascular endothelial growth
factor and its soluble reseptor VEGFR-1 and VEGFR-2 levels in the
sera of small cell lung cancer patients. Med Oncol. 25:394–399.
2008. View Article : Google Scholar : PubMed/NCBI
|
